{"id":"viaject","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"VIAject combines human insulin with a patented diluent containing an excipient (likely citrate or similar) that enhances subcutaneous absorption kinetics, allowing faster peak insulin levels and shorter time-to-action compared to conventional insulin formulations. This rapid onset is intended to better match postprandial glucose excursions in diabetic patients.","oneSentence":"VIAject is a rapid-acting insulin formulation that uses a proprietary excipient system to accelerate insulin absorption and onset of action.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:35.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07423637","phase":"NA","title":"The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2026-04-01","conditions":"Type 1 Diabetes","enrollment":100},{"nctId":"NCT07470905","phase":"NA","title":"Development and Preclinical Validation of DiaBuddy, a Point-of-Care Decision Support Tool for Children With Type 1 Diabetes: A Pilot Clinical Study","status":"COMPLETED","sponsor":"Regency Hospital Kanpur","startDate":"2025-07-01","conditions":"Type 1 Diabetes (T1D)","enrollment":25},{"nctId":"NCT07463417","phase":"NA","title":"Evaluating the SWW Method Dietary Intervention for HbA1c and Weight Management as a Preventative Intervention in Women","status":"COMPLETED","sponsor":"Sarah Wragge Wellness","startDate":"2024-04-01","conditions":"Metabolic Syndrome, Obesity & Overweight, Blood Glucose Monitoring","enrollment":85},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT06645834","phase":"NA","title":"Smart MDI Study (CIP343)","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2024-12-06","conditions":"Diabetes Mellitus, Type 1","enrollment":179},{"nctId":"NCT07227805","phase":"NA","title":"Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)","status":"NOT_YET_RECRUITING","sponsor":"Medtronic Diabetes","startDate":"2026-06-15","conditions":"Diabetes (Insulin-requiring, Type 1 or Type 2)","enrollment":116},{"nctId":"NCT06411548","phase":"NA","title":"InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2025-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":7},{"nctId":"NCT06604871","phase":"NA","title":"Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2024-10-29","conditions":"Type 1 Diabetes","enrollment":56},{"nctId":"NCT05815342","phase":"NA","title":"OP5-005 Using Omnipod 5 in Adults With Type 2","status":"COMPLETED","sponsor":"Insulet Corporation","startDate":"2023-04-11","conditions":"Type2 Diabetes","enrollment":343},{"nctId":"NCT05059860","phase":"","title":"Dexcom Hybrid Closed Loop Insulin Pump Study in Type 1 Diabetes","status":"COMPLETED","sponsor":"NHS Lothian","startDate":"2023-06-09","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT05114590","phase":"PHASE4","title":"Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-01-27","conditions":"Type 2 Diabetes Mellitus","enrollment":124},{"nctId":"NCT07141472","phase":"NA","title":"Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study","status":"COMPLETED","sponsor":"Lawry Han","startDate":"2025-01-07","conditions":"Blood Sugar; High, Overweight and Obesity, Fat Loss","enrollment":69},{"nctId":"NCT05224258","phase":"NA","title":"Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2022-03-17","conditions":"Type 1 Diabetes","enrollment":240},{"nctId":"NCT06858475","phase":"","title":"Long-term Observation Of Patient Engagement in Automated Insulin Delivery","status":"COMPLETED","sponsor":"Centre Hospitalier Sud Francilien","startDate":"2025-03-20","conditions":"Type 1 Diabetes Mellitus","enrollment":453},{"nctId":"NCT02274571","phase":"EARLY_PHASE1","title":"Raising Insulin Sensitivity in Post Menopause","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2015-09","conditions":"Menopause","enrollment":8},{"nctId":"NCT06837103","phase":"","title":"Real-world Effects of Using Intermittently Scanned Continuous Glucose Monitoring and Pharmacist-led Coaching on the Management of Type 2 Diabetes Among Adults Not Using Insulin (REAL isCGM T2D)","status":"RECRUITING","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2025-04-09","conditions":"Type 2 Diabetes","enrollment":250},{"nctId":"NCT04196140","phase":"NA","title":"Pivotal Omnipod Horizon™ Automated Glucose Control System","status":"COMPLETED","sponsor":"Insulet Corporation","startDate":"2019-12-30","conditions":"Type 1 Diabetes Mellitus","enrollment":240},{"nctId":"NCT05238142","phase":"NA","title":"In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2022-02-25","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":574},{"nctId":"NCT05714059","phase":"NA","title":"Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2023-02-28","conditions":"Type 1 Diabetes","enrollment":250},{"nctId":"NCT04252482","phase":"NA","title":"Validation of Sleep Healthcare System","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2020-02-07","conditions":"Obstructive Sleep Apnea","enrollment":52},{"nctId":"NCT05325294","phase":"NA","title":"Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2022-05-05","conditions":"Type 1 Diabetes","enrollment":244},{"nctId":"NCT04809285","phase":"NA","title":"Use of the Guardian™ Connect System With Smart Connected Devices","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2021-04-06","conditions":"Type 1 Diabetes Mellitus","enrollment":217},{"nctId":"NCT05399134","phase":"NA","title":"Glycemic Evaluation of Novel Staple Foods","status":"COMPLETED","sponsor":"National University of Singapore","startDate":"2021-01-01","conditions":"Diabete Type 2, Diabetes Mellitus","enrollment":20},{"nctId":"NCT01231984","phase":"NA","title":"Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles","status":"COMPLETED","sponsor":"Becton, Dickinson and Company","startDate":"2010-10","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":293},{"nctId":"NCT02285985","phase":"PHASE4","title":"Effects of Saxagliptin on Adipose Tissue Inflammation in Humans","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2013-02","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":103},{"nctId":"NCT04476472","phase":"NA","title":"Omnipod Horizon™ Automated Glucose Control System Preschool Cohort","status":"COMPLETED","sponsor":"Insulet Corporation","startDate":"2020-09-08","conditions":"Type 1 Diabetes Mellitus","enrollment":80},{"nctId":"NCT06236256","phase":"NA","title":"Advanced Hybrid Closed Loop System (AHCL) in Older Patients With Type 1 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2024-01-09","conditions":"Diabetes Mellitus, Type 1","enrollment":40},{"nctId":"NCT06207838","phase":"NA","title":"Transition of T1DM Patients Aged Over 65 Years Into AHCL (780G) Insulin Pump","status":"UNKNOWN","sponsor":"Jagiellonian University","startDate":"2023-09-14","conditions":"Diabetes Type 1","enrollment":30},{"nctId":"NCT05029271","phase":"NA","title":"InPen User Experience","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2023-04-17","conditions":"Diabetes Type 1","enrollment":34},{"nctId":"NCT04742023","phase":"EARLY_PHASE1","title":"Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-04-21","conditions":"Diabetes Mellitus","enrollment":40},{"nctId":"NCT00655200","phase":"","title":"Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-02","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":2286},{"nctId":"NCT04176731","phase":"NA","title":"Prepivotal Omnipod Horizon™ Automated Glucose Control System","status":"COMPLETED","sponsor":"Insulet Corporation","startDate":"2019-12-15","conditions":"Type 1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT00849316","phase":"","title":"Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2009-02","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT06074965","phase":"NA","title":"Impact of Two Medtronic Infusion Sets on Lipohypertrophy in Type 1 Diabetes (T1DM) Patients Thought to Have LH","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Camillo Forlanini","startDate":"2022-10-05","conditions":"Diabetes, Diabetes Mellitus, Type 1, Lipohypertrophy","enrollment":16},{"nctId":"NCT04964128","phase":"NA","title":"Evaluation of Meal Gesture Dosing in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2021-07-22","conditions":"Type 1 Diabetes","enrollment":28},{"nctId":"NCT04663295","phase":"NA","title":"MiniMed™ 670G System China Study for Type I Diabetic","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2020-10-31","conditions":"Diabetes Mellitus, Type 1","enrollment":74},{"nctId":"NCT01613807","phase":"PHASE4","title":"Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-10","conditions":"Gestational Diabetes Mellitus","enrollment":40},{"nctId":"NCT03767543","phase":"PHASE3","title":"Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":265},{"nctId":"NCT03434119","phase":"PHASE3","title":"Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-02-20","conditions":"Type 2 Diabetes Mellitus","enrollment":241},{"nctId":"NCT05096325","phase":"","title":"YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion","status":"COMPLETED","sponsor":"mylife Diabetes Care AG","startDate":"2022-01-03","conditions":"Diabetes Mellitus, Type 1","enrollment":40},{"nctId":"NCT04591925","phase":"NA","title":"SteadiSet™ Pilot Study (SteP Study)","status":"TERMINATED","sponsor":"Capillary Biomedical, Inc.","startDate":"2021-02-05","conditions":"Diabetes Mellitus, Type I, IDDM, Diabetes Mellitus, Insulin-Dependent, 1","enrollment":13},{"nctId":"NCT03478969","phase":"NA","title":"Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-05-17","conditions":"Diabetes Mellitus, Type 1","enrollment":181},{"nctId":"NCT03815487","phase":"NA","title":"Comparison of Two Management Systems in Patients With Type 1 Diabetes (Pediatric SmartHome)","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2018-11-19","conditions":"Patient Care, Drug Therapy","enrollment":40},{"nctId":"NCT02897557","phase":"NA","title":"Insulet Artificial Pancreas Early Feasibility Study","status":"COMPLETED","sponsor":"Insulet Corporation","startDate":"2016-09","conditions":"Type 1 Diabetes","enrollment":59},{"nctId":"NCT03953963","phase":"NA","title":"Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Medality Medical","startDate":"2019-10-18","conditions":"Diabetes Mellitus, Type 2, Insulin Resistance","enrollment":12},{"nctId":"NCT04659330","phase":"NA","title":"Lipohypertrophy Monitoring Study","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2018-06-01","conditions":"Diabetes Mellitus, Lipohypertrophy, Hypoglycemia","enrollment":171},{"nctId":"NCT04616391","phase":"NA","title":"AHCL System Initiation in T1D Patients naïve to Technology","status":"UNKNOWN","sponsor":"Jagiellonian University","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 1","enrollment":40},{"nctId":"NCT04115579","phase":"NA","title":"The Impact of Low Glycaemic Index (GI) Biscuits on Postprandial Glycaemia Using the Continuous Glucose Monitoring System (CGMS™) (Biscuit Study (BIS) Study)","status":"COMPLETED","sponsor":"Singapore Institute of Food and Biotechnology Innovation","startDate":"2019-02-20","conditions":"Diabetes Mellitus, Type 2, Diabetes","enrollment":14},{"nctId":"NCT03653533","phase":"NA","title":"Evaluation of the Function \"Stop Before Hypoglycemia\" on External Insulin Pump","status":"TERMINATED","sponsor":"ARAIR Assistance","startDate":"2019-01-07","conditions":"Type I Diabetes","enrollment":8},{"nctId":"NCT03816761","phase":"PHASE2","title":"Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-02-25","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT02846831","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-01-24","conditions":"Type 1 Diabetes","enrollment":36},{"nctId":"NCT04421001","phase":"NA","title":"RCT for Evaluation of Insulin Administration,While Using the iPORT System","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2020-10","conditions":"T1DM","enrollment":35},{"nctId":"NCT03424044","phase":"PHASE1","title":"Three Way Crossover Closed Loop Study With Xeris Glucagon","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2018-03-29","conditions":"Type1diabetes","enrollment":23},{"nctId":"NCT03878745","phase":"NA","title":"Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle","status":"COMPLETED","sponsor":"Becton, Dickinson and Company","startDate":"2019-02-11","conditions":"Diabetes","enrollment":55},{"nctId":"NCT03878758","phase":"NA","title":"Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles","status":"COMPLETED","sponsor":"Becton, Dickinson and Company","startDate":"2019-02-07","conditions":"Diabetes","enrollment":158},{"nctId":"NCT02660242","phase":"PHASE2","title":"The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 1","enrollment":16},{"nctId":"NCT02733991","phase":"NA","title":"Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2016-12","conditions":"Type 1 Diabetes","enrollment":153},{"nctId":"NCT00919633","phase":"PHASE2","title":"Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C","status":"COMPLETED","sponsor":"Medtronic Corporate Technologies and New Ventures","startDate":"2009-06","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT03755232","phase":"NA","title":"Acute Glycemic and Insulinemic Response of FOSSENCE™","status":"COMPLETED","sponsor":"TATA CHEMICALS LTD","startDate":"2018-12-06","conditions":"Dietary Modification, Healthy","enrollment":25},{"nctId":"NCT04073576","phase":"NA","title":"Assessment of Two Insulin Pump Insulin Delivery Systems in Type 1 Diabetes.","status":"UNKNOWN","sponsor":"Christchurch Clinical Studies Trust Ltd","startDate":"2019-05-20","conditions":"Type1diabetes","enrollment":60},{"nctId":"NCT02752113","phase":"PHASE3","title":"Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2016-04","conditions":"Diabetes Mellitus Type 2","enrollment":101},{"nctId":"NCT02846857","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT01513473","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-16","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":350},{"nctId":"NCT01952145","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-20","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":557},{"nctId":"NCT01676116","phase":"PHASE3","title":"The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":438},{"nctId":"NCT01059812","phase":"PHASE3","title":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":424},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT01991470","phase":"NA","title":"CEP249 Pediatric Accuracy Study","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2015-03","conditions":"Insulin Requiring Diabetes","enrollment":186},{"nctId":"NCT02059187","phase":"PHASE3","title":"The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-11","conditions":"Type 2 Diabetes Mellitus","enrollment":531},{"nctId":"NCT02059174","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-10","conditions":"Type 1 Diabetes Mellitus","enrollment":76},{"nctId":"NCT02059161","phase":"PHASE3","title":"A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-17","conditions":"Type 1 Diabetes Mellitus","enrollment":508},{"nctId":"NCT03608995","phase":"NA","title":"Diagnostic Tests in the Context of Threatened Preterm Labour","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2018-08-21","conditions":"Preterm Labor, Immunochromatographic Assay, Predictive Value of Tests","enrollment":220},{"nctId":"NCT00872560","phase":"PHASE3","title":"Comparison of 2 NovoFine® Needles on the Reflux of Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-01-20","conditions":"Diabetes, Diabetes Mellitus, Type 1, Delivery Systems","enrollment":60},{"nctId":"NCT02230618","phase":"","title":"Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-11-24","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1029},{"nctId":"NCT02636491","phase":"NA","title":"Use of an Automated Insulin Delivery System Compared to Sensor Augmented Pump at Patients With Type 1 Diabetes (T1D)","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2015-12","conditions":"Type 1 Diabetes","enrollment":45},{"nctId":"NCT02488616","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-03","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT03411460","phase":"NA","title":"Satisfaction of Hospitalized Diabetic Patients Using a Continuous Glucose Monitoring System","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-04-19","conditions":"Insulin-Dependent Diabetes","enrollment":10},{"nctId":"NCT02451917","phase":"PHASE4","title":"Glargine Versus NPH in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":34},{"nctId":"NCT03375398","phase":"NA","title":"Determination of the PPG and Insulin Responses of Rice Alone and Rice Consumed With Sugardown™","status":"COMPLETED","sponsor":"Boston Therapeutics","startDate":"2011-03","conditions":"Postprandial Hyperglycemia","enrollment":10},{"nctId":"NCT03374501","phase":"NA","title":"Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™","status":"COMPLETED","sponsor":"Boston Therapeutics","startDate":"2014-11","conditions":"Postprandial Hyperglycemia","enrollment":10},{"nctId":"NCT02490098","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-01","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02657083","phase":"NA","title":"Prevention of Hypoglycemia After Exercise Using Closed Loop System in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT03070704","phase":"","title":"Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2017-08-16","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT00395343","phase":"PHASE3","title":"Sitagliptin Added-on to Insulin Study (0431-051)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-11","conditions":"Type 2 Diabetes Mellitus","enrollment":641},{"nctId":"NCT02662842","phase":"","title":"BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study","status":"COMPLETED","sponsor":"Becton, Dickinson and Company","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":75},{"nctId":"NCT01849289","phase":"PHASE3","title":"A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-06-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":833},{"nctId":"NCT00972283","phase":"PHASE3","title":"Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1006},{"nctId":"NCT00982228","phase":"PHASE3","title":"Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":629},{"nctId":"NCT01059799","phase":"PHASE3","title":"Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":435},{"nctId":"NCT01111370","phase":"NA","title":"Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System","status":"COMPLETED","sponsor":"DexCom, Inc.","startDate":"2010-02","conditions":"Diabetes Mellitus","enrollment":60},{"nctId":"NCT00978627","phase":"PHASE3","title":"Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":548},{"nctId":"NCT01045447","phase":"PHASE3","title":"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":465},{"nctId":"NCT01272193","phase":"PHASE3","title":"Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":296},{"nctId":"NCT01365507","phase":"PHASE3","title":"Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":276},{"nctId":"NCT02045290","phase":"PHASE3","title":"Insulin Clamp Ancillary Study for Assessment of Insulin Resistance","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2014-01","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT00659295","phase":"","title":"Observational Study to Evaluate the Safety of Levemir® in Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":51170},{"nctId":"NCT01068678","phase":"PHASE3","title":"Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":460},{"nctId":"NCT01364428","phase":"PHASE3","title":"Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":373},{"nctId":"NCT01074268","phase":"PHASE3","title":"Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":456},{"nctId":"NCT01326026","phase":"PHASE3","title":"Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VIAject™","genericName":"VIAject™","companyName":"Biodel","companyId":"biodel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VIAject is a rapid-acting insulin formulation that uses a proprietary excipient system to accelerate insulin absorption and onset of action. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}